ManlaYosef Profile Banner
Yosef Manla, MD, FESC Profile
Yosef Manla, MD, FESC

@ManlaYosef

Followers
258
Following
2K
Media
48
Statuses
173

Incoming IM PGY-1 | Postdoc-Scientist @SmidtHeart-@CedarsSinai | Former Research Scholar @ Cleveland Clinic @CCAD| FESC @escardio |

Los Angeles, CA
Joined May 2021
Don't wanna be here? Send us removal request.
@ManlaYosef
Yosef Manla, MD, FESC
1 month
Grateful for the opportunity to contribute to the latest ISHLT Consensus Statement on antibodies and antibody-mediated rejection after heart transplantation, led by Dr. Jon Kobashigawa @SmidtHeart and Dr Andreas Zuckermann. 🫀In memory of Dr. @JigPatelMDPhD .Link to statement :
Tweet media one
Tweet media two
Tweet media three
0
1
15
@ManlaYosef
Yosef Manla, MD, FESC
3 months
RT @robmentz: Don't let great research stall. With JCF Express: Court of Appeals you can submit your previously reviewed manuscript for an….
0
12
0
@ManlaYosef
Yosef Manla, MD, FESC
3 months
Presented this at #ISHLT2025: In our single-center study @SmidtHeart , pre- heart transplant sensitization & older donor age were associated with immediate presentation of severe PGD-LV ⚠️. Immediate presentation = worse 30-day & 1-yr survival vs delayed presentation 📉.@ISHLT
Tweet media one
Tweet media two
1
5
14
@ManlaYosef
Yosef Manla, MD, FESC
3 months
RT @SaraInglisMBBCh: Does Time Matter in #PGD presentation? @ISHLT @ManlaYosef . ➡️ Study shows worse outcomes in immediate vs. delayed pre….
0
2
0
@ManlaYosef
Yosef Manla, MD, FESC
3 months
Presenting our case series on variable responses to daratumumab for pre-transplant desensitization in adult heart transplant candidates #ISHLT2025 @ISHLT @SmidtHeart #transplantimmunology
Tweet media one
1
2
7
@ManlaYosef
Yosef Manla, MD, FESC
3 months
2/🧵.🌍 Key themes identified:. • 📊 Lack of high-quality, region-specific HF registry data.• 🏥Balancing accessible care vs. centralized specialized care.• ✅ Need for HF care accreditation & coordination across delivery centers.• ⏱️ Improving prevention & timely diagnosis,.
0
0
0
@ManlaYosef
Yosef Manla, MD, FESC
3 months
Excited to share our recent paper summarizing @HFSA global roundtable discussions on heart failure innovation. Link: Grateful for the mentorship of Dr. Bader & Dr. Vest @NutritionHF and the opportunity to collaborate with HF Societies & leaders 🇺🇸 🇨🇦 🇨🇴
Tweet media one
1
2
3
@ManlaYosef
Yosef Manla, MD, FESC
6 months
RT @XMichaelJonesMD: New online! 🗒️Pleased to share that our State-of-the-Art Review on SSc associated cardiovascular disease is now publis….
journals.sagepub.com
Cardiovascular complications are observed in up to one-third of patients with systemic sclerosis (SSc). Early identification and management of SSc-associated pr...
0
5
0
@ManlaYosef
Yosef Manla, MD, FESC
7 months
RT @XMichaelJonesMD: Excited to share that our paper “Macrophages Contribute to Cardiac Fibrosis and Diastolic Dysfunction in Systemic Scle….
0
16
0
@ManlaYosef
Yosef Manla, MD, FESC
7 months
I am excited to share our recent publication @TheJHLT, demonstrating how therapeutic plasma exchange improves survival in patients experiencing severe primary graft dysfunction after heart transplantation. Link: Beyond grateful to my mentor,
Tweet media one
Tweet media two
1
9
32
@ManlaYosef
Yosef Manla, MD, FESC
8 months
RT @datsunian: One of my unintended passions is now exploring: How do we make #cardioonc succeed, 1 program at a time?. @yosefmanla @DSadle….
0
1
0
@ManlaYosef
Yosef Manla, MD, FESC
8 months
So happy to reconnect with You, Obada! Keep up the great work!.
@obada_kholoki
Obada Kholoki
8 months
Another highlight from the conference was reuniting with a great friend and my research mentor @ManlaYosef, whose contributions to the research surrounding Heart Failure continue to be profoundly impactful.
Tweet media one
0
0
1
@ManlaYosef
Yosef Manla, MD, FESC
8 months
Presenting our findings on predictors of Ischemia reperfusion injury post heart transplant #AHA24 @SmidtHeart @CedarsSinaiMed . We found that: Optimal prioritization of HTx candidates on the waitlist and use of ATG induction therapy seem to protect against immediate ischemia
Tweet media one
3
1
15
@ManlaYosef
Yosef Manla, MD, FESC
8 months
RT @JanetWeiMD: Great #AHA2024 presentation from @CedarsCards Dr. Rashmi Jain: Highly sensitized patients treated with desensitization pri….
0
3
0
@ManlaYosef
Yosef Manla, MD, FESC
8 months
Conclusion: Our study hints at better 5-year survival in HKTx recipients receiving pre-transplant D-MCS, which could be attributed to the findings of lower rates of AMR in this population.
0
0
1
@ManlaYosef
Yosef Manla, MD, FESC
8 months
Presenting our findings on "Five-year Outcomes of Heart-Kidney Transplant Recipients Bridged with Durable MCS" grateful to the mentorship of Dr.Kobashigawa and the team @SmidtHeart @CedarsSinai @CedarsSinaiMed #AHA24
Tweet media one
1
0
11
@ManlaYosef
Yosef Manla, MD, FESC
8 months
I am excited to present this weekend at the American Heart Association Scientific Sessions 2024 #AHA24! in Chicago! Celebrating 100 years of Cardiology science and hope! @AHAMeetings @AHAScience @SmidtHeart
Tweet media one
@ManlaYosef
Yosef Manla, MD, FESC
1 year
Excited to share that our work @SmidtHeart on ischemia-reperfusion injury post-heart transplant, as well as our study on heart-kidney transplant patients bridged with D-MCS, has been selected for 3 moderated presentations at the American Heart Association Scientific Sessions
Tweet media one
2
1
12
@ManlaYosef
Yosef Manla, MD, FESC
9 months
RT @IHME_UW: GBD data highlights Pulmonary Arterial Hypertension (PAH)'s substantial burden worldwide, affecting women at a higher rate tha….
0
4
0
@ManlaYosef
Yosef Manla, MD, FESC
1 year
Excited to share that our work @SmidtHeart on ischemia-reperfusion injury post-heart transplant, as well as our study on heart-kidney transplant patients bridged with D-MCS, has been selected for 3 moderated presentations at the American Heart Association Scientific Sessions
Tweet media one
3
1
12